Latest Breaking News On - Paulr edick - Page 3 : comparemela.com

Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023

Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSteven pieperPaulr edickExchange commissionXeris biopharma holdings incConference callBiopharma raises full year financial guidanceReaffirms cash flow breakevenBiopharma holdingsHorizon therapeuticsChief financial officerXeris biopharma holdingsPrivate securities litigation reform actQuarterly report

Xeris Pharmaceuticals Inc (XERS) Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4

Xeris Pharmaceuticals Inc (XERS) Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Steven pieperPaulr edickXeris biopharma holdings incXeris biopharma holdingsHorizon therapeuticsChief financial officer

Xeris Biopharma Holdings, Inc (NASDAQ:XERS) Insider Purchases $23,800 00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Paul R. Edick bought 10,000 shares of Xeris Biopharma stock in a transaction that occurred on Wednesday, August 9th. The shares were bought at an average cost of $2.38 per share, with a total value of $23,800.00. Following the acquisition, the insider now directly owns […]

United statesPaulr edickXeris biopharmaXeris biopharma holdings incOsaic holdings incGoldstein advisorsCetera advisor networksVirtu financialXeris biopharma holdingsGet free reportBiopharma holdingsAdvisor networksXeris biopharma dailyNasdaq xersInsider tradingNsider trades

Xeris Ships One Millionth Gvoke Unit

31.07.2023 - Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Xeris has . Seite 1

United statesGvoke hypopenPaulr edickXeris biopharma holdings incAmerican diabetes associationXeris biopharma holdingsXeri chairmanAmerican diabetesGvoke kit

Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism
wsiltv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wsiltv.com Daily Mail and Mail on Sunday newspapers.

United statesPaulr edickAllison weyKennethe johnsonXeris biopharma holdingsExchange commissionXeris biopharma holdings incGlobal developmentCorporate communicationsBiopharma holdingsXeri chairmanXeri senior vice presidentTitration periodMaintenance periodPrivate securities litigation reform actQuarterly report